Intercept to Present at Upcoming Investor Conference in October
Get Alerts ICPT Hot Sheet
Join SI Premium – FREE
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conference:
Cantor Global Healthcare Conference at 9:30 a.m. ET on Friday, October 4, 2019.
Webcast information for this event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An archived webcast will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Lisa DeFrancesco
+1-646-565-4833
Media inquiries: [email protected]
Source: Intercept Pharmaceuticals, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Castle.com Is Bridging Gambling and Video Games, and Building an Entire World Around It
- Data I/O Proposes to Acquire Embedded Software Security Assets from IAR
- Save the Date: 7-Eleven, Inc. Celebrates 60 Years of Slurpee® Tomorrow with Free Drinks and a New Flavor on the Coolest Slurpee Day Yet
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share